Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:40 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)
NCT06333678 · Memorial Sloan Kettering Cancer Center · PHASE2 · terminated · last registry update 2026-09-02 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study closed by Amgen due to lack of enrollment” | – | Registry record, Memorial Sloan Kettering Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD274 in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-10Also stopped (suspended): National Cancer Institute (NCI), azacytidine + carboplatin (NCT06694454)
- 2026-11-10Results posted on the registry: William Zeitler, Durvalumab + Pharmacological ascorbate (NCT06083454)
- 2026-11-10Also stopped (terminated): William Zeitler, Durvalumab + Pharmacological ascorbate (NCT06083454)
- 2026-11-09Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Tiragolumab (NCT04294810)
- 2026-11-02Phase 3 first posted: Merck Sharp & Dohme LLC, Gocatamig + Durvalumab (NCT07908537)
- 2026-10-26Phase 3 first posted: Suzhou Suncadia Biopharmaceuticals Co., Ltd., SHR-A1811 Injection + Adebrelimab Injection (NCT07896005)
- 2026-10-26Phase 3 first posted: West China Hospital, Adebrelimab (SHR-1316) + chemotherapy + Adebrelimab (NCT07895238)
- 2026-10-09Results posted on the registry: Hoffmann-La Roche, Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody + Placebo Comparator (NCT03456063)
- 2026-10-06Results posted on the registry: National Cancer Institute (NCI), Atezolizumab (NCT04214262)
- 2026-10-06Results posted on the registry: Washington University School of Medicine, Paclitaxel + Carboplatin AUC (NCT03916419)
- 2026-09-25Results posted on the registry: CellCentric Ltd., CCS1477 + Abiraterone acetate (NCT03568656)
- 2026-09-23Results posted on the registry: Alliance Foundation Trials, LLC., Durvalumab (NCT04062708)
- 2026-09-22Also stopped (terminated): National Cancer Institute (NCI), Olaparib + Durvalumab (NCT04538378)
- 2026-09-18Also stopped (suspended): Dwight Owen, Atezolizumab + Vismodegib (NCT06616623)
- 2026-09-16Phase 3 first posted: Jiangsu Hansoh Pharmaceutical Co., Ltd., HS-10370 + Adebrelimab (NCT07822542)
- 2026-09-14Results posted on the registry: Canadian Cancer Trials Group, MEDI4736 + Placebo (NCT02273375)
- 2026-09-14Also stopped (suspended): University of Maryland, Baltimore, Durvalumab 50 MG/1 ML Intravenous Solution + Etoposide Injection (NCT05403723)
- 2026-08-31Phase 3 first posted: Zai Lab (Shanghai) Co., Ltd., ZL-1310 in combination with Atezolizumab or Durvalumab + Carboplatin/Etoposide in Combination with Atezolizumab followed by maintenance Atezolizumab with Lurbinectedin (NCT07796100)
- 2026-08-11Results posted on the registry: National Cancer Institute (NCI), Atezolizumab + Cobimetinib (NCT03600701)
- 2026-07-28Results posted on the registry: M.D. Anderson Cancer Center, Durvalumab + Selumetinib (NCT03581487)
- 2026-06-04Phase 3 first posted: SystImmune Inc., BL-M14D1 and Atezolizumab + Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin (NCT07625644)
- 2026-04-28Phase 3 first posted: Merck Sharp & Dohme LLC, Calderasib + Durvalumab (NCT07554339)
- 2026-03-16Phase 3 first posted: Boehringer Ingelheim, obrixtamig + atezolizumab (NCT07472517)
- 2026-01-23Phase 3 first posted: Bristol-Myers Squibb, Pumitamig + Durvalumab (NCT07361497)
- 2025-12-29Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Lurbinectedin (NCT05091567)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision